Mesenchymal Stem Cells for Frailty Syndrome

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 3, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Pathologic Processes

Interventions

BIOLOGICAL

umbilical cord mesenchymal stem cells

Patients assigned to UC-MSC administration groups will receive one administrations

Trial Locations (2)

Taipei Veterans General Hospital, Taipei

National Taiwan University Hospital, Taipei

All Listed Sponsors

lead

Meribank Biotech Co., Ltd.

INDUSTRY

NCT06501066 - Mesenchymal Stem Cells for Frailty Syndrome | Biotech Hunter | Biotech Hunter